FacebookTwitterRedditEmail

Bush Report on Drug Imports

Some recent headlines:

“HHS reports drug imports likely won’t save money.”

“Net saving on drug import not worth action.”

“Legalizing drug imports not worth it.”

“Bush panel sees scant savings in drug imports.”

These were based on a report released two weeks ago by the Department of Health and Human Services which concluded that “total savings to drug buyers from legalized commercial importation would be 1 to 2 percent of total drug spending.”

If this were true, reimportation of drugs would never take off. Why, then, would the drug industry spend so much time fighting this plan? What is it that the drug companies know but that the Department of Health and Human Services doesn’t want you to understand?

The answer is that the data in the report don’t support the department’s conclusions.

The research in the report actually indicates the possibility of saving 17.5 percent, or $37.8 billion, annually in the United States. And this also explains the drug industry’s fear of importation.

The department’s conclusion that reimportation will not result in significant savings is built on the premise as stated in the report that “imported drugs may be around 12 percent of total use … because drug companies have incentives to impede exports.” This assumption doesn’t take into account that reimportation bills would make it illegal to limit supply something the drug companies are keenly aware of but the Department of Health and Human Services completely forgot.

The second faulty premise is that “U.S. drug buyers may get discounts of only 20 percent or less, with the rest of the difference between U.S. and foreign prices going to commercial importers.”

This statement should be contrasted with a chart in the report showing that U.S. retail drug prices are 100 percent higher than in Europe. So this premise assumes unprecedented price gouging by importers and a complete lack of competition among them. Of course, the drug industry knows that is not how the free market works, but the Department of Health and Human Services feigns ignorance.

The third premise in the report is that “about 30 percent of total drug spending may be unchanged by legalizing commercial importation because about that much is now spent on products that are inappropriate for importation.” According to the report, these would include such drugs as those used during surgery, those that are injected, controlled substances or low-cost generics.

Let’s now do the analysis of savings possible in the United States, based on the data in the report. We know that according to the report drug prices in Europe are at least 50 percent lower than in the United States. Let’s be very conservative and assume as much as half of this price difference is captured by greedy importers a pretty unlikely scenario because with such costs, reimportation would never have existed within Europe.

Then we take the report’s premise that 30 percent of the U.S. market will not have competition from reimported drugs because they are generics or belong to categories that can’t be imported easily.

That leaves 70 percent of the market multiplied by a 25 percent price reduction, for a saving of 17.5 percent on the total U.S. drug bill of $216 billion, resulting in a net saving of $37.8 billion.

This is a simplified analysis, but more complex mathematical models based on the Department of Health and Human Services’ research data result in similar savings. In summary, the report has the right data but the wrong conclusions.

PETER ROST is a vice president of marketing at Pfizer; the views expressed here are his own.

More articles by:

bernie-the-sandernistas-cover-344x550

Weekend Edition
April 19, 2019
Friday - Sunday
Andrew Levine
What Will It Take For Trump to Get His Due?
Roy Eidelson
Is the American Psychological Association Addicted to Militarism and War?
Jeffrey St. Clair
Roaming Charges: Time is Blind, Man is Stupid
Joshua Frank
Top 20 Mueller Report “Findings”
Rob Urie
Why Russiagate Will Never Go Away
Paul Street
Stephen Moore Gets Something Right: It’s Capitalism vs. Democracy
Russell Mokhiber
Why Boeing and Its Executives Should be Prosecuted for Manslaughter
T.J. Coles
The Battle for Latin America: How the U.S. Helped Destroy the “Pink Tide”
Ron Jacobs
Ho Chi Minh City: Nguyen Thai Binh Street
Dean Baker
Fun Fictions in Economics
David Rosen
Trump’s One-Dimensional Gender Identity
Kenn Orphan
Notre Dame: We Have Always Belonged to Her
Robert Hunziker
The Blue Ocean Event and Collapsing Ecosystems
Theodore C. Van Alst, Jr.
Paddy Wagon
Brett Wilkins
Jimmy Carter: US ‘Most Warlike Nation in History of the World’
John W. Whitehead
From Jesus Christ to Julian Assange: When Dissidents Become Enemies of the State
Nick Pemberton
To Never Forget or Never Remember
Stephen Cooper
My Unforgettable College Stabbings
Louis Proyect
A Leftist Rejoinder to the “Capitalist Miracle”
Louisa Willcox
Aldo Leopold’s Land Ethic and the Need for a New Approach to Managing Wildlife
Brian Cloughley
Britain Shakes a Futile Fist and Germany Behaves Sensibly
Jessicah Pierre
A Revolutionary Idea to Close the Racial Wealth Divide
George Burchett
Revolutionary Journalism
Dan Bacher
U.S. Senate Confirms Oil Lobbyist David Bernhardt as Interior Secretary
Nicky Reid
The Strange Success of Russiagate
Chris Gilbert
Defending Venezuela: Two Approaches
Todd Larsen
The Planetary Cost of Amazon’s Convenience
Kelly Martin
How the White House is Spinning Earth Day
Nino Pagliccia
Cuba and Venezuela: Killing Two Birds With a Stone
Matthew Stevenson
Pacific Odyssey: Guadalcanal and Bloody Ridge, Solomon Islands
David Kattenburg
Trudeau’s Long Winter
Gary Olson
A Few Comments on the recent PBS Series: Reconstruction: America After the Civil War
Ellen Lindeen
What Does it Mean to Teach Peace?
Adewale Maye and Eileen Appelbaum
Paid Family and Medical Leave: a Bargain Even Low-Wage Workers Can Afford
Ramzy Baroud
War Versus Peace: Israel Has Decided and So Should We
Ann Garrison
Vets for Peace to Barbara Lee: Support Manning and Assange
Thomas Knapp
The Mueller Report Changed my Mind on Term Limits
Jill Richardson
Why is Going Green So Hard? Because the System Isn’t
Mallika Khanna
The Greenwashing of Earth Day
Arshad Khan
Do the Harmless Pangolins Have to Become Extinct?
Paul Armentano
Pushing Marijuana Legalization Across the Finish Line
B. R. Gowani
Surreal Realities: Pelosi, Maneka Gandhi, Pompeo, Trump
Paul Buhle
Using the Law to Build a Socialist Society
David Yearsley
Call Saul
Elliot Sperber
Ecology Over Economy 
FacebookTwitterRedditEmail